![Figure 1. PKC412 induces apoptosis of HMCLs. (A) MTS assay data for HMCLs treated with PKC412 (0.1-20μM) for 24 and 72 hours. (⊡ indicates NCI-H929; ▨, OPM2; , RPMI-8226; [▪], KMS-11; □, U266; and ▪ LP-1). Graph represents data from 3 individual experiments *P values versus U266, **P values versus LP-1 [NCI-H929: *P < .001, **P = .001; OPM2: *P < .001, **P < .001; RPMI-8226: *P < .001, **P = .002; KMS-11: *P < .001, **P = .019], Student t test). (B) Live cells after 72 hours of treatment with 1 and 3 μM PKC412 was determined by annexin V–FITC/propidium iodide flow cytometry (⊡ indicates NCI-H929; ▪, LP-1). Graph represents data from 3 individual experiments. (C) Whole-cell lysates of cells treated with 2 μM (2) and 4 μM (4) PKC412 were analyzed for PARP cleavage by Western blot (CF indicates cleaved fragment; D, DMSO). Image is a representative of 2 experiments shown. (D) PKC activity in HMCLs measured after 24 and 72 hours of treatment with 5 μM PKC412 (⊡ indicates NCI-H929; [▪], OPM2; and □, U266; *P = .009, .036, and .001, respectively, versus untreated samples, Student t test, graph represents results from 3 experiments). Error bars for all graphs indicate standard error of the mean (SEM).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/109/4/10.1182_blood-2006-05-014092/4/zh80040708260001.jpeg?Expires=1743077734&Signature=dP9TMs-GEaeMxLI6~dpNUq8cVhE4Am65J5bKT5kXjHFDcpufOLrySpL8nrB46NqDW-uh2D3MXaWWddK2M1snbvgdn~ha4kR6xamRhlrI4DI3B9zqEGgq1CRB5lpntXPIbfrC9gBki6lUFoCuIcnUgZ8B1Fxm3ceYhYxjtJuVh3GiwVbukZcmLkzIJOQqxIoGRbEc~qE53RSJs9Rn0YNO9KpnqsGxVFmDGbDE-2n2ar2w~k1TCJsRJ6QEQdyRhAyXLL1LMYKgbNqC9oLnzeo~YS1f1qfiMMufSIJzNMmm5icsyvnnNpQONjCoAMQTFTfw1SzH6AG9fDsG3ek89DPxqg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
PKC412 induces apoptosis of HMCLs. (A) MTS assay data for HMCLs treated with PKC412 (0.1-20μM) for 24 and 72 hours. (⊡ indicates NCI-H929; ▨, OPM2; , RPMI-8226; [▪], KMS-11; □, U266; and ▪ LP-1). Graph represents data from 3 individual experiments *P values versus U266, **P values versus LP-1 [NCI-H929: *P < .001, **P = .001; OPM2: *P < .001, **P < .001; RPMI-8226: *P < .001, **P = .002; KMS-11: *P < .001, **P = .019], Student t test). (B) Live cells after 72 hours of treatment with 1 and 3 μM PKC412 was determined by annexin V–FITC/propidium iodide flow cytometry (⊡ indicates NCI-H929; ▪, LP-1). Graph represents data from 3 individual experiments. (C) Whole-cell lysates of cells treated with 2 μM (2) and 4 μM (4) PKC412 were analyzed for PARP cleavage by Western blot (CF indicates cleaved fragment; D, DMSO). Image is a representative of 2 experiments shown. (D) PKC activity in HMCLs measured after 24 and 72 hours of treatment with 5 μM PKC412 (⊡ indicates NCI-H929; [▪], OPM2; and □, U266; *P = .009, .036, and .001, respectively, versus untreated samples, Student t test, graph represents results from 3 experiments). Error bars for all graphs indicate standard error of the mean (SEM).
